These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 24897555)

  • 41. Bortezomib-induced perivascular dermatitis in a patient with multiple myeloma.
    Ozkurt ZN; Sucak GT; Aki SZ; Yağci M; Erdem O
    Cutan Ocul Toxicol; 2009; 28(3):141-3. PubMed ID: 19548772
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Different dose combinations of bortezomib and dexamethasone in the treatment of relapsed or refractory myeloma: an open-label, observational, multi-center study in China.
    Yuan ZG; Jin J; Huang XJ; Li Y; Chen WM; Liu ZG; Chen XQ; Shen ZX; Hou J
    Chin Med J (Engl); 2011 Oct; 124(19):2969-74. PubMed ID: 22040537
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Antitumor effects of proteasome inhibition in anaplastic thyroid carcinoma.
    Altmann A; Markert A; Askoxylakis V; Schöning T; Jesenofsky R; Eisenhut M; Haberkorn U
    J Nucl Med; 2012 Nov; 53(11):1764-71. PubMed ID: 23055533
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Bortezomib: new indication. Second-line treatment of myeloma: limited efficacy, major risks.
    Prescrire Int; 2006 Jun; 15(83):98-100. PubMed ID: 16764098
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Bortezomib-induced skin eruption.
    Sanchez-Politta S; Favet L; Kerl K; Dietrich PY; Piguet V
    Dermatology; 2008; 216(2):156-8. PubMed ID: 18216478
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Probing the specificity and activity profiles of the proteasome inhibitors bortezomib and delanzomib.
    Berkers CR; Leestemaker Y; Schuurman KG; Ruggeri B; Jones-Bolin S; Williams M; Ovaa H
    Mol Pharm; 2012 May; 9(5):1126-35. PubMed ID: 22432738
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Proteasome inhibitor, bortezomib, potently inhibits the growth of adult T-cell leukemia cells both in vivo and in vitro.
    Satou Y; Nosaka K; Koya Y; Yasunaga JI; Toyokuni S; Matsuoka M
    Leukemia; 2004 Aug; 18(8):1357-63. PubMed ID: 15190257
    [TBL] [Abstract][Full Text] [Related]  

  • 48. High serum bone-specific alkaline phosphatase level after bortezomib-combined therapy in refractory multiple myeloma: possible role of bortezomib on osteoblast differentiation.
    Shimazaki C; Uchida R; Nakano S; Namura K; Fuchida SI; Okano A; Okamoto M; Inaba T
    Leukemia; 2005 Jun; 19(6):1102-3. PubMed ID: 15830008
    [No Abstract]   [Full Text] [Related]  

  • 49. Human metabolism of the proteasome inhibitor bortezomib: identification of circulating metabolites.
    Pekol T; Daniels JS; Labutti J; Parsons I; Nix D; Baronas E; Hsieh F; Gan LS; Miwa G
    Drug Metab Dispos; 2005 Jun; 33(6):771-7. PubMed ID: 15764713
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Treatment with a proteasome inhibitor, bortezomib, for thalidomide-resistant multiple myeloma].
    Takatoku M; Noborio-Hatano K; Takahashi S; Kikuchi S; Mori M; Muroi K; Komatsu N; Ozawa K
    Rinsho Ketsueki; 2004 Feb; 45(2):144-8. PubMed ID: 15045823
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Gold nanoparticle delivery-enhanced proteasome inhibitor effect in adenocarcinoma cells.
    Coelho SC; Rocha S; Juzenas P; Sampaio P; Almeida GM; Silva FS; Pereira MC; Coelho MA
    Expert Opin Drug Deliv; 2013 Oct; 10(10):1345-52. PubMed ID: 23937147
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Bortezomib directly inhibits osteoclast function in multiple myeloma: implications into the management of myeloma bone disease.
    Terpos E
    Leuk Res; 2008 Nov; 32(11):1646-7. PubMed ID: 18614229
    [No Abstract]   [Full Text] [Related]  

  • 53. Home administration of bortezomib: making a difference to myeloma patients' lives.
    Meenaghan T; O'Dwyer M; Hayden P; Hayat A; Murray M; Dowling M
    Eur J Oncol Nurs; 2010 Apr; 14(2):134-6. PubMed ID: 19818684
    [No Abstract]   [Full Text] [Related]  

  • 54. Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression.
    Orlowski RZ; Nagler A; Sonneveld P; Bladé J; Hajek R; Spencer A; San Miguel J; Robak T; Dmoszynska A; Horvath N; Spicka I; Sutherland HJ; Suvorov AN; Zhuang SH; Parekh T; Xiu L; Yuan Z; Rackoff W; Harousseau JL
    J Clin Oncol; 2007 Sep; 25(25):3892-901. PubMed ID: 17679727
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Re-transplantation after bortezomib-based therapy.
    Morris C; Cook G; Streetly M; Kettle P; Drake M; Quinn M; Cavet J; Tighe J; Kazmi M; Ashcroft J; Cook M; Snowden J; Olujohungbe A; Marshall S; Conn J; Oakervee H; Popat R; Cavenagh J
    Br J Haematol; 2011 Jun; 153(5):666-8. PubMed ID: 21275960
    [No Abstract]   [Full Text] [Related]  

  • 56. Enhancing proteasome-lnhibitor effect by functionalized gold nanoparticles.
    Coelho SC; Rocha S; Pereira MC; Juzenas P; Coelho MA
    J Biomed Nanotechnol; 2014 Apr; 10(4):717-23. PubMed ID: 24734524
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Bortezomib congeners induce apoptosis of hepatocellular carcinoma via CIP2A inhibition.
    Hou DR; Huang AC; Shiau CW; Wang CY; Yu HC; Chen KF
    Molecules; 2013 Dec; 18(12):15398-411. PubMed ID: 24335617
    [TBL] [Abstract][Full Text] [Related]  

  • 58. High XBP1 expression is a marker of better outcome in multiple myeloma patients treated with bortezomib.
    Gambella M; Rocci A; Passera R; Gay F; Omedè P; Crippa C; Corradini P; Romano A; Rossi D; Ladetto M; Boccadoro M; Palumbo A
    Haematologica; 2014 Feb; 99(2):e14-6. PubMed ID: 24497562
    [No Abstract]   [Full Text] [Related]  

  • 59. Development of P22 viral capsid nanocomposites as anti-cancer drug, bortezomib (BTZ), delivery nanoplatforms.
    Min J; Moon H; Yang HJ; Shin HH; Hong SY; Kang S
    Macromol Biosci; 2014 Apr; 14(4):557-64. PubMed ID: 24847525
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Transplantation for myeloma: work in progress.
    Palumbo A
    J Clin Oncol; 2012 Aug; 30(24):2935-6. PubMed ID: 22802317
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.